2. Search Result
Search Result
Results for "

LPA1

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18076
    LPA1 receptor antagonist 1

    		LPL Receptor Infection Inflammation/Immunology
    LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 (LPA1) antagonist with an IC50 of 25 nM.
    LPA1 receptor antagonist 1
  • HY-117959
    TAK-615

    		LPL Receptor Inflammation/Immunology
    TAK-615 is a negative allosteric modulator (NAM) of the LPA1 receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (Kd high affinity of 1.7 nM and Kd low affinity of 14.5 nM) [1].
    TAK-615
  • HY-150204
    ONO-0740556

    		LPL Receptor Inflammation/Immunology
    ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC50 value of 0.26 nM [1].
    ONO-0740556
  • HY-120478
    ASP6432

    		LPL Receptor Infection
    ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC50s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively [1].
    ASP6432
  • HY-16040
    AM095 free acid
    5+ Cited Publications

    		 LPL Receptor Inflammation/Immunology
    AM095 (free acid) is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.
    AM095 free acid
  • HY-16039
    AM095
    5+ Cited Publications

    		 LPL Receptor Inflammation/Immunology
    AM095 is a selective LPA1 receptor antagonist. The IC50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells is 0.025 and 0.023 μM, respectively.
    AM095
  • HY-139853
    BMS-986278
    1 Publications Verification

    		 LPL Receptor Others
    BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases [1].
    BMS-986278
  • HY-15277
    AM966
    Maximum Cited Publications
    16 Publications Verification

    		 LPL Receptor Inflammation/Immunology
    AM966 is a high affinity, selective, oral LPA1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC50=17 nM).
    AM966
  • HY-138453
    ACT-1016-0707

    LPA1 receptor antagonist 2

    		 LPL Receptor Inflammation/Immunology
    ACT-1016-0707 (Compound 49) is an orally active and selective LPA1 receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases [1].
    ACT-1016-0707
  • HY-167862
    UCM-05194

    		Endogenous Metabolite Neurological Disease
    UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases [1].
    UCM-05194
  • HY-100882
    ONO-7300243

    		LPL Receptor Cardiovascular Disease
    ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.
    ONO-7300243
  • HY-117444
    ONO-9780307

    		LPL Receptor Cancer
    ONO-9780307 is a specific synthetic LPA1 (lysophosphatidic acid receptor 1) antagonist with an IC50 value of 2.7 nM [1].
    ONO-9780307
  • HY-15706
    H2L 5765834

    		LPL Receptor Cardiovascular Disease
    H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA1, LPA3, and LPA5, with IC50s of 94, 752, and 463 nM respectively [1].
    H2L 5765834
  • HY-129808
    VPC12249

    		LPL Receptor Cardiovascular Disease Cancer
    VPC12249 is a competitive dual LPA1/LPA3 antagonist with Ki values of 137nM and 428 nM, respectively. VPC12249 inhibits calcium mobilization in HEK293T cells with a Ki value of ~130 nM. VPC12249 is promising for research of ovarian cancer and hypertensive diseases [1].
    VPC12249
  • HY-115450
    ONO-0300302

    		LPL Receptor Endocrinology Cancer
    ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC50 of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with Kd of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research [1].
    ONO-0300302
  • HY-18641
    Ki16198

    		LPL Receptor Cancer
    Ki16198 is a potent and orally active LPA receptor antagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA1 and LPA3-induced inositol phosphate production with?Ki?values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo [1].
    Ki16198
  • HY-114379
    AS2717638
    1 Publications Verification

    		 LPL Receptor Neurological Disease Inflammation/Immunology
    AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC50 value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases [1] .
    AS2717638
  • HY-100619A
    BMS-986020 sodium
    5+ Cited Publications

    AM152 sodium

    		 LPL Receptor Metabolic Disease Inflammation/Immunology
    BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist [1]. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020 sodium
  • HY-100619
    BMS-986020
    5+ Cited Publications

    AM152

    		 LPL Receptor Metabolic Disease Inflammation/Immunology
    BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist [1]. BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020
  • HY-13285
    Ki16425
    5+ Cited Publications

    Debio 0719

    		 LPL Receptor YAP Neurological Disease Cancer
    Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK [1] . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .
    Ki16425
  • HY-119013
    VPC32183

    		Endogenous Metabolite Cardiovascular Disease
    VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. The activity of VPC32183 can inhibit lipid phosphatase 1 (LPP1), thereby preventing the activation of ERK(1/2) by dioctanoic acid diglyceride (DGPP 8:0). By reducing the expression of LPP1, VPC32183 can further reduce DGPP 8:0-induced ERK(1/2) activation. The effects of VPC32183 suggest that it may have a positive regulatory function in cell signaling processes [1].
    VPC32183
  • HY-124072
    HL001

    		Cyclophilin LPL Receptor MDM-2/p53 Apoptosis Reactive Oxygen Species Cancer
    HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis [1] .
    HL001
  • HY-W923661
    1-Octadecyl lysophosphatidic acid

    PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA

    		 LPL Receptor Others
    1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects [1].
    1-Octadecyl lysophosphatidic acid
  • HY-137862
    1-Oleoyl lysophosphatidic acid
    1 Publications Verification

    1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA

    		 LPL Receptor Neurological Disease
    1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the LPA receptors. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA receptor activation [1]. 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .
    1-Oleoyl lysophosphatidic acid
  • HY-157617
    16:0 Cyclic LPA ammonium

    1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate ammonium

    		 Biochemical Assay Reagents Others
    16:0 Cyclic LPA (1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate) ammonium is a palmitoyl cyclic phosphatidic acid [1].
    16:0 Cyclic LPA ammonium
  • HY-157669
    1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium

    18:1 Cyclic LPA

    		 Biochemical Assay Reagents Others
    1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic phosphatidic acid that can be used for the preparation of liposomes [1].
    1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium
  • HY-150614
    Autotaxin-IN-6

    		Phosphodiesterase (PDE) LPL Receptor Cancer
    Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC50 value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer [1].
    Autotaxin-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: